Recent Developments in Biologic Therapies for the Treatment of Patients with Systemic Lupus Erythematosus

Detalhes bibliográficos
Autor(a) principal: Carreira, P
Data de Publicação: 2019
Outros Autores: Isenberg, D
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.17/3913
Resumo: SLE has a complex pathogenesis, and multiple therapeutic targets have been discovered in recent years. In spite of belimumab being approved by the US Food and Drug Administration and the widespread use of rituximab, there have been many failed attempts to treat SLE successfully using biologic agents. In this review, we consider newer biologic approaches that might offer the hope of improving the outcome of SLE patients. These include the fully humanized anti-CD20 mAbs, PEGylated anti-CD40L, IFNα inhibitors, rigerimod and immune complexes blockade.
id RCAP_e711842b5bdad5be6574c131bef9ec75
oai_identifier_str oai:repositorio.chlc.min-saude.pt:10400.17/3913
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Recent Developments in Biologic Therapies for the Treatment of Patients with Systemic Lupus ErythematosusHCC DAUTOIMAntibodies, Monoclonal, Humanized / therapeutic useBiological Products / therapeutic use*HumansImmunoglobulin Fab Fragments / therapeutic useImmunologic Factors / therapeutic use*Interferon-alpha / therapeutic useLupus Erythematosus, Systemic / drug therapy*Polyethylene Glycols / therapeutic useRituximab / therapeutic useTreatment OutcomeSLE has a complex pathogenesis, and multiple therapeutic targets have been discovered in recent years. In spite of belimumab being approved by the US Food and Drug Administration and the widespread use of rituximab, there have been many failed attempts to treat SLE successfully using biologic agents. In this review, we consider newer biologic approaches that might offer the hope of improving the outcome of SLE patients. These include the fully humanized anti-CD20 mAbs, PEGylated anti-CD40L, IFNα inhibitors, rigerimod and immune complexes blockade.Oxford University PressRepositório do Centro Hospitalar Universitário de Lisboa Central, EPECarreira, PIsenberg, D2021-11-22T15:30:42Z20192019-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/3913engRheumatology (Oxford). 2019 Mar 1;58(3):382-387.10.1093/rheumatology/key064.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:44:36Zoai:repositorio.chlc.min-saude.pt:10400.17/3913Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:21:13.418726Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Recent Developments in Biologic Therapies for the Treatment of Patients with Systemic Lupus Erythematosus
title Recent Developments in Biologic Therapies for the Treatment of Patients with Systemic Lupus Erythematosus
spellingShingle Recent Developments in Biologic Therapies for the Treatment of Patients with Systemic Lupus Erythematosus
Carreira, P
HCC DAUTOIM
Antibodies, Monoclonal, Humanized / therapeutic use
Biological Products / therapeutic use*
Humans
Immunoglobulin Fab Fragments / therapeutic use
Immunologic Factors / therapeutic use*
Interferon-alpha / therapeutic use
Lupus Erythematosus, Systemic / drug therapy*
Polyethylene Glycols / therapeutic use
Rituximab / therapeutic use
Treatment Outcome
title_short Recent Developments in Biologic Therapies for the Treatment of Patients with Systemic Lupus Erythematosus
title_full Recent Developments in Biologic Therapies for the Treatment of Patients with Systemic Lupus Erythematosus
title_fullStr Recent Developments in Biologic Therapies for the Treatment of Patients with Systemic Lupus Erythematosus
title_full_unstemmed Recent Developments in Biologic Therapies for the Treatment of Patients with Systemic Lupus Erythematosus
title_sort Recent Developments in Biologic Therapies for the Treatment of Patients with Systemic Lupus Erythematosus
author Carreira, P
author_facet Carreira, P
Isenberg, D
author_role author
author2 Isenberg, D
author2_role author
dc.contributor.none.fl_str_mv Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE
dc.contributor.author.fl_str_mv Carreira, P
Isenberg, D
dc.subject.por.fl_str_mv HCC DAUTOIM
Antibodies, Monoclonal, Humanized / therapeutic use
Biological Products / therapeutic use*
Humans
Immunoglobulin Fab Fragments / therapeutic use
Immunologic Factors / therapeutic use*
Interferon-alpha / therapeutic use
Lupus Erythematosus, Systemic / drug therapy*
Polyethylene Glycols / therapeutic use
Rituximab / therapeutic use
Treatment Outcome
topic HCC DAUTOIM
Antibodies, Monoclonal, Humanized / therapeutic use
Biological Products / therapeutic use*
Humans
Immunoglobulin Fab Fragments / therapeutic use
Immunologic Factors / therapeutic use*
Interferon-alpha / therapeutic use
Lupus Erythematosus, Systemic / drug therapy*
Polyethylene Glycols / therapeutic use
Rituximab / therapeutic use
Treatment Outcome
description SLE has a complex pathogenesis, and multiple therapeutic targets have been discovered in recent years. In spite of belimumab being approved by the US Food and Drug Administration and the widespread use of rituximab, there have been many failed attempts to treat SLE successfully using biologic agents. In this review, we consider newer biologic approaches that might offer the hope of improving the outcome of SLE patients. These include the fully humanized anti-CD20 mAbs, PEGylated anti-CD40L, IFNα inhibitors, rigerimod and immune complexes blockade.
publishDate 2019
dc.date.none.fl_str_mv 2019
2019-01-01T00:00:00Z
2021-11-22T15:30:42Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/3913
url http://hdl.handle.net/10400.17/3913
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Rheumatology (Oxford). 2019 Mar 1;58(3):382-387.
10.1093/rheumatology/key064.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Oxford University Press
publisher.none.fl_str_mv Oxford University Press
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131308405817344

Registros relacionados